SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices surge to new highs, driven by a weakening dollar and global economic uncertainty. Community discussions revolve around whether this rally is sustainable or indicative of a larger market bubble, with some anticipating a significant correction while others remain bullish due to geopolitical tensions and potential Federal Reserve actions.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions around potential HR downsizing and restructuring efforts, possibly linked to increased AI spending. The community is analyzing technical indicators for potential trading strategies, while also debating the company's valuation and future growth prospects in a competitive tech landscape. Some traders are expressing frustration with the stock's recent performance.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as traders debate its correlation to Bitcoin's price movements and potential S&P 500 inclusion, with some expressing frustration over its recent performance. Community members are actively discussing dip-buying opportunities and potential catalysts, including speculation around a Joe Rogan podcast appearance by Michael Saylor. Concerns linger about dilution and the stock's ability to capture Bitcoin's upside, while others remain bullish, citing long-term potential and accumulation phases.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors discuss its potential transition into an AI infrastructure play, fueled by the launch of Black Pearl Phase 1 and rumors of a hyperscaler deal. Community members are weighing the risks and opportunities, with some suggesting profit-taking while others advocate holding for long-term gains in the data center sector. The stock's volatility and sensitivity to broader market trends are also key talking points.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing (RGTI) is trending amid volatility and a significant price correction after a substantial run-up, with community discussions focused on whether this marks the end of the quantum computing hype cycle or a buying opportunity. Concerns about high valuations, potential stock dilution, and insiders selling shares are being weighed against the long-term potential of quantum computing and recent endorsements from major financial institutions. Some traders are betting against the stock, while others remain bullish, anticipating a rebound.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending as the community debates its valuation and recent partnerships, including a deal with Swiss Quantum Technology SA. While some express concerns about insider selling and question the company's revenue, others highlight its technology advancements and potential for future growth in the quantum computing sector. The stock's high volatility and the broader discussion around quantum computing's commercial viability are also fueling the conversation.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders react to market volatility and potential trade tensions, with community members actively discussing hedging strategies and positioning for potential market downturns. The ETF's price action and its relationship to broader market indices like the SPY are also being closely monitored. Some traders express concerns about the ETF's management and performance relative to the VIX.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending due to volatility following a recent equity offering, sparking debate among traders about whether it represents smart growth funding or potential shareholder dilution. Community members are actively discussing the company's drone and AI technology, its potential impact on the defense sector, and the possibility of a significant rebound or further downside.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc (QUBT) is trending amid ongoing debates about the viability and valuation of quantum computing stocks, with discussions focusing on the company's financial health after a recent capital raise. Some community members are questioning the necessity of raising so much capital and highlighting potential dilution risks, while others express optimism about QUBT's technology and future prospects in the sector. Comparisons with sector peers like IONQ and RGTI are common, with some arguing QUBT has more room to run.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending due to positive Phase 3 trial results for its essential tremor treatment, sparking significant community discussion about its potential and future prospects. While some traders are optimistic about the stock's potential for further gains, others are wary of a potential offering and are considering short positions, contributing to the volatility and heightened interest in the stock. Analyst upgrades and potential peak sales are being heavily discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months 

Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.


LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's 'Best Inventions of 2025' LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's 'Best Inventions of 2025' PR...

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.

Global Leaders Jess Mantas and Wes Bricker Join NACD Board of Directors

Global Leaders Jess Mantas and Wes Bricker Join NACD Board of Directors Global Leaders Jess Mantas and Wes Bricker Join NACD Board of Directors PR Newswire WASHINGTON, Oct. 10, 2025 Seasoned...

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today...

Can BMYs Neuroscience Portfolio Help to Diversify Its Business? 

Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.

LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy

Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.

U.S. President Donald Trump said on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting Oct. 1 unless manufacturers are actively building plants in the country.&nbsp;As part of a series of late-night posts on Truth Social on Thursday,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">Trump said</a> the exemption will apply only to firms that have “broken ground” or are “under construction.” “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”&nbsp;The announcement intensifies the administration’s push to shift drug manufacturing to the U.S. Last month, Trump said the U.S. would begin with a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">“small tariff”</a> on imported drugs before raising duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had previously been exempt from Trump’s reciprocal tariff program; however, the new duties will apply to prescription drugs, biologics, specialty medicines, and over-the-counter products, except for generic drugs, which remain excluded.Major drugmakers have responded unevenly.&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> has committed more than $50 billion since 2020 to U.S. expansion, including $27 billion for four new “mega sites.” The company supports maintaining the U.S. as the “world’s leading destination for biopharmaceutical research and manufacturing” and agrees with the administration’s goal of more fairly sharing drug costs across developed countries, even as it warns that broad tariffs could raise costs and limit access.Lilly’s stream on Stocktwits gained traction late Thursday after Trump’s announcement, with sentiment tilting ‘bullish’ as retail traders bet that the company would benefit from the latest federal policy. “$LLY did great with plant announcement in houston this week. They wont have tariffs,”&nbsp;<a href="https://stocktwits.com/Gorohanada/message/630073275">said</a> one user.Several users noted that Novo Nordisk, Regeneron and Thermo Fisher also have U.S. sites that could qualify. Some argued investors misunderstand Novo’s footprint, contributing to its recent weakness despite likely exemptions.<stembedurl>https://stocktwits.com/3rdtimeretired/message/630071784</stembedurl><stembedurl>https://stocktwits.com/Bullish_Trader555/message/630067344</stembedurl><stembedurl>https://stocktwits.com/oldmanrizzer/message/630072277</stembedurl>AstraZeneca and Roche each announced plans this summer to invest $50 billion in new or expanded facilities across multiple states. Merck has invested more than $12 billion in U.S. manufacturing since 2017 and plans to invest an additional $9 billion by 2028, while Biogen has pledged $2 billion to upgrade its North Carolina plants.Others have taken a more cautious stance. Pfizer stated in March that it could shift overseas production to existing U.S. sites if necessary, but has not committed to new investment, whereas Novo Nordisk has yet to announce major U.S. projects.&nbsp;Trump’s Thursday night post followed the launch of fresh national security probes into imports of robotics, industrial machinery, and medical devices. The Commerce Department said on Wednesday that it launched investigations on Sept. 2 to determine if these imports could pose a risk to U.S. national security.&nbsp;On Stocktwits, retail sentiment for the SPDR S&amp;P Biotech ETF (XBI) was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/XBI">XBI</a> has risen 6.5%. So far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.

Equity

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal

Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

BIIB
Biogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BIIB News

BIIBBiogen Inc